

On-line Table: Characteristics of all patients (N = 185)

Characteristics	VEGF Expression			P Value ^a
	Total	--~++ (n = 103)	+++ (n = 82)	
Age				
Median (range) (yr)	50 (20–77)	52 (20–77)	49 (21–69)	
50 or older/younger than 50	94/91	53/50	41/41	.844
Sex				
Men/women	119:66	74:29	45:37	.017
KPS score				
80 or higher/lower than 80	122/63	76/27	46/36	.012
Tumor volume (mm ³)				
Mean ± SD	52,064 ± 32725	49,675 ± 28341	57,014 ± 40473	.033 ^b
Brain region involvement ^c (involved/uninvolved)				
Frontal lobe	81/137	50/77	31/60	.424
Temporal lobe	84/134	46/81	38/53	.407
Parietal lobe	44/174	23/104	21/70	.368
Insular	9/209	8/119	1/90	.119
Pattern of enhancement				
Ringlike/non-ringlike	124/61	62/41	62/20	.027
Peritumoral edema				
Yes/no	129/56	68/35	61/21	.218
nCET				
Yes/no	74/111	36/67	38/44	.116
IDH1 mutation				
Yes/no	16/169	10/93	6/76	.565
MGMT expression				
Yes/no	85/22	52/16	33/6	.316
EGFR expression				
Yes/no	73/29	48/20	25/9	.756
Extent of resection				
GTR/<GTR	112/73	53/50	59/23	.005
Adjuvant therapy				
Standard therapy ^d /non-standard therapy	141/44	76/27	65/17	.384

Note:—MGMT indicates *O*6-methylguanine DNA methyltransferase; IDH1, *isocitrate dehydrogenase 1*; EGFR, epidermal growth factor receptor.

^a Result of the χ^2 test. *P* value of .05 denotes significance.

^b Result of a *t* test. *P* value of .05 denotes significance.

^c The frequency of tumor involvement in each brain lobe.

^d Standard therapy includes concomitant temozolomide administration with fractionated radiotherapy followed by up to 6 cycles of adjuvant temozolomide.